Phesgo market forecast points to steady growth through 2035

The Business Research Company says the global Phesgo market is set to expand as breast cancer diagnoses rise and demand grows for subcutaneous, personalized oncology treatments. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Phesgo targets HER2-positive breast cancer, a large and growing treatment area in oncology. - Market growth is tied to rising breast cancer incidence, wider use of targeted biologics, and a shift toward more convenient subcutaneous delivery. - The forecast suggests demand will be shaped not just by drug performance, but by patient preference, care settings, and treatment efficiency.

What happened: - The Business Research Company released its Phesgo Global Market Report 2026, covering market size, trends, and a forecast for 2026-2035. - The report says the Phesgo market is expected to grow steadily over the forecast period. - Phesgo is a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase for subcutaneous injection. - The therapy is indicated for HER2-positive breast cancer in early-stage and metastatic settings, often with chemotherapy. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Historical market growth has been driven by higher diagnosis rates of HER2-positive breast cancer. - Additional tailwinds include improvements in monoclonal antibody therapies, growth in oncology infusion centers, better survival from targeted treatments, and more biologic drug approvals. - Future growth is expected to benefit from home-based oncology care models, more investment in combination biologics, wider acceptance of subcutaneous drug delivery, and progress in formulation stability technologies. - The report identifies broader use of fixed-dose combination treatments as a key forecast trend. - Patient convenience and adherence are expected to become a stronger market focus. - The report links Phesgo demand to the rising prevalence of breast cancer. - Breast cancer cases in the U.S. increased from 300,590 in 2023 to 313,510 in 2024, according to the American Cancer Society. - The report also ties demand to personalized medicine, which customizes treatment based on genetic, lifestyle, and environmental factors. - The Personalized Medicine Coalition reported 16 new personalized treatments approved by the FDA in 2023 for rare diseases, including seven cancer drugs, up from six approvals in 2022. - Geographic coverage in the report includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis.

Between the lines: - The market story is shifting from pure clinical need to delivery advantages, with subcutaneous administration positioned as a practical differentiator. - Home-based oncology care could broaden access and change where treatment is delivered, not just which therapies are used. - North America's lead suggests strong current adoption, while Asia-Pacific's growth outlook points to expanding access and diagnosis rates rather than saturation.

What's next: - The report expects more adoption of fixed-dose combinations and subcutaneous oncology therapies as treatment models evolve. - Biologic investment and formulation improvements could support broader use of Phesgo-style regimens. - Providers and manufacturers are likely to watch whether convenience-led care models accelerate uptake in outpatient and home settings. - More information is available in the full report and a free sample.